A NGIOTENSIN II (Ang II) participates in the regulation of fluid and electrolyte homeostasis, hormone secretion from the anterior and the posterior pituitary gland, and in the central control of the autonomic nervous system, through receptors present within the brain and many peripheral tissues (1) (2) (3) . The AT 1 site is the physiologically active Ang II receptor, mediating most, if not all, the wellknown functions of Ang II (4) . The AT 2 site is highly expressed in peripheral fetal tissues, in the immature brain and, in adult rodents, in the adrenal medulla (3) . This site has been proposed to be involved in the regulation of growth and to cross-talk with the AT 1 receptor (3, 5, 6) . The physiological function of the AT 2 receptors has not yet been clarified, and the experimental evidence is equivocal (3, 5) .
Ang II participates in the regulation of the stress reaction at all levels of the hypothalamic-pituitary-adrenal axis. Stress increases the production of circulating Ang II (7) and the expression of Ang II AT 1 receptors in brain areas crucial for the central control of the stress reaction such as the hypothalamic paraventricular nucleus (8, 9) , in the anterior pituitary gland, and in the adrenal medulla (10) . These findings indicate that the Ang II AT 1 receptor mediates the regulation of the stress reaction by Ang II (9) .
In the adrenal medulla, Ang II releases catecholamines by a direct action (11) , mediated either by circulating Ang II or by the intrinsic adrenal renin angiotensin system (11) (12) (13) . Both AT 1 and AT 2 Ang II receptors are expressed in the adrenal medulla. In the rat, AT 2 receptors predominate, AT 1 receptors representing only 5-10% of the total number of Ang II receptors (14) . It appears that AT 1 receptor stimulation is most important as a regulatory factor for adrenomedullary catecholamine synthesis and release. First, AT 1 blockade is sufficient to inhibit in vivo adrenal catecholamine release by Ang II (15) . Second, pretreatment with an insurmountable AT 1 antagonist almost completely abolished the hormonal and sympathoadrenal response to the stress of isolation in unfamiliar metabolic cages (16) . However, isolation stress also produced a substantial increase in adrenomedullary AT 2 receptor binding, abolished by pretreatment with the AT 1 receptor antagonist (16) . This indicated a possible role of AT 2 receptors in the adrenomedullary response to stress.
In cultured bovine adrenomedullary cells, Ang II increases catecholamine biosynthesis, producing acute activation of rat tyrosine hydroxylase (TH) and increased expression of the genes coding for this enzyme (17) . Regulation of TH activity involves short-term posttranscriptional mechanisms (18) , whereas long-term regulation involves transcriptional activation of the TH gene (19) by multiple factors and promoter elements. The participation of these mechanisms in the proposed Ang II-mediated regulation of TH transcription has not been fully characterized.
We wished to clarify the physiological role of Ang II and its receptor types, under basal conditions, on the molecular mechanisms of regulation of TH transcription in the adrenal medulla, including the family of proteins binding to the 
Materials and Methods

Animals and preparation of tissues
Wistar Hanover male rats (8 wk old) were purchased from Taconic Farms, Inc. (Germantown, NY), were kept at 22 C under a 12-h dark, 12-h light cycle with lights on at 0700 h and were given free access to normal rat diet and tap water. The National Institute of Mental Health (NIMH) Animal Care and Use Committees approved all procedures.
Rats were anesthetized with pentobarbital (30 mg/kg) and Alzet osmotic minipumps (Alza Scientific Products, Palo Alto, CA) were implanted subcutaneously. Groups of ten animals (treated) received minipumps containing vehicle, the AT 1 receptor antagonist candesartan (Astra USA, Inc., Wedel, Germany) dissolved in 1 mol/liter sodium carbonate and further diluted in isotonic saline, at a final pH of 7.5-8.0, to be delivered at a rate of 1.0 mg/kg⅐d, or the AT 2 receptor antagonist PD 123319 (Sigma-Aldrich Corp., St. Louis, MO; 1 mg/kg⅐d), respectively. While candesartan is an insurmountable antagonist with longterm effects (23) , the half-life of PD 123319 is short (24) . For this reason, doses and routes of administration of the receptor antagonists were selected to provide continuous receptor blockade and to obtain approximately equal degrees of inhibition for each receptor type. After minipump implantation the rats were kept in their cages in groups of three to four under standard conditions with regular rat food and water ad libitum for 14 d. At the end of the experiment the animals were killed by decapitation and adrenal glands were removed, frozen in isopentane at -30 C on dry ice, and stored at -80 C until used.
Autoradiography of Ang II receptor subtypes
Consecutive sections from adrenal gland, 16 m-thick, were cut in a cryostat at Ϫ20 C and thaw-mounted on gelatinized slides, dehydrated overnight in a desiccator at 4 C, and kept at Ϫ80 C until used. Binding experiments were performed as described earlier (23) . Sections were preincubated for 15 min in 10 mm sodium phosphate buffer (pH 7.4), containing 120 mm NaCl, 5 mm EDTA, 0.005% bacitracin, and 0.2% BSA. After preincubation, slides were transferred to fresh buffer containing 0. 5 (25, 26) .
In situ hybridization of tyrosine hydroxylase mRNA
We used one antisense (TH-AS) of 48-oligomer for TH cDNA sequence localized in nucleotides 1562-1609 (27; Lofstrand Labs Ltd., Gaithersburg, MD). Labeling was performed with a 3Ј-end labeling kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) using terminal deoxynucleotidyl transferase to a specific activity of 3-4 ϫ 10 8 dpm/g. Each reaction was performed with 70 pmol of oligonucleotides in the presence of 70 Ci of [␣- 35 S]ATP (Amersham Pharmacia Biotech). The labeled oligonucleotides were separated from unincorporated nucleotides using MicroSpin G-25 columns (Amersham Pharmacia Biotech). In situ hybridization of rat adrenal sections and posthybridization washings were performed as described (28) . In situ hybridization was performed in consecutive adrenal sections, one incubated with the TH-AS oligonucleotide and another with excess unlabeled TH-AS probe (157 pmol/ml). After the washing, sections were dehydrated in alcohols containing 0.3 m ammonium acetate, air dried, and exposed to Kodak Biomax MR. The films were developed and quantified as described above by comparison with [
14 C] standards (American Radiolabeled Chemicals, Inc.).
Western blot analysis
After dissection of the adrenal cortex and medulla, tissues were homogenized on ice in buffer containing 10 mm Tris (pH 7.4), 1% sodium dodecyl sulfate, and protease inhibitors (Protease Inhibitor Cocktail, Roche, Mannheim, Germany) and the homogenate was centrifuged at 1800 ϫ g for 5 min at 4 C. Protein concentration was determined by the Bradford procedure (Bio-Rad Laboratories, Inc., Hercules, CA). Proteins were fractionated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA). After blocking with 5% nonfat dried milk (Bio-Rad Laboratories, Inc., Hercules, CA) in Tris-buffered saline (100 mm Tris-Cl, pH 7.5; and 100 mm NaCl) containing 0.1% Tween 20 (TBS-T) for 1 h, the membranes were incubated with appropriate amounts of the primary antibody [anti-Fra-2 (Fos-related antigen 2], anti-AT 1 
Catecholamine determinations in adrenal glands
The content of adrenal norepinephrine (NE) and epinephrine (E) was determined by reverse-phase HPLC with electrochemical detection in aliquots of adrenal supernatants (29) . Sample catechols were partially purified by batch alumina extraction, separated by HPLC using a 4.6 ϫ 250 mm Zorbax RxC18 column (DuPont Co., Wilmington, DE) and quantified amperometrically by the current produced upon exposure of the column effluent to oxidizing and then reducing potentials in series using a triple-electrode system (ESA, Bedford, MA). Recovery through the alumina extraction step averaged 70 -80% for E and NE. Catechol concentrations in each sample were corrected for recovery of an internal standard, dihydroxybenzylamine. The limit of detection was about 15 pg/vol assayed for each catechol.
Colocalization studies
Dual immunofluorescent labeling was employed for simultaneous demonstration of two antigens. Briefly, frozen section of adrenal gland were air dried, fixed with cold acetone for 5 min, and washed with PBS. The sections were then incubated overnight with primary antibodies followed by secondary antibodies conjugated with fluorescein isothiocyanate or Texas red (Vector Laboratories, Burlingame, CA). Nuclei were stained with 2,6Ј-diamidino-4-phenyl-indole (Vector Laboratories). For AT 1 receptor immunohistochemistry, we used a monoclonal antibody against the third internal loop of the human AT 1 receptor, amino acids 229 -246 (no. 4H2; Ref. 30) . The specificity of the antibody was validated by dot blot assay, by Western blot analysis of whole adrenal protein, and by immunohistochemistry in sections of the rat adrenal gland. The AT 1 receptor antibody reacted with both the AT 1A and AT 1B peptides (amino acids 229 -246), and there was no crossreactivity against the AT 2 peptide (amino acids 314 -330). In addition, the AT 1 receptor antibody detected a prominent band with an apparent molecular mass of 73 kDa, consistent with that of the AT 1 receptor, and detected the presence of AT 1 receptors in the rat adrenal cortex and medulla (30) . For AT 2 receptor immunohistochemistry, we used a goat polyclonal antibody against the carboxy terminus of the AT 2 receptors (no. C-18 from Santa Cruz Biotechnology, Inc.). For Ang II immunohistochemistry, we used an Ang II mouse monoclonal antibody (4B3) validated by dot-blot assay (30) . In experiments for colocalization of Ang II receptor types and Ang II we used a rabbit polyclonal antibody raised against amino acids 306 -359 of the AT 1 receptor from Santa Cruz Biotechnology, Inc., and antibodies against the AT 2 receptor and Ang II as described above. Control procedures (omission of the primary antibody and substitution of this antibody for normal IgG of the same animal species) gave negative results. Three-color fluorescence imaging was accomplished using a laser scanning confocal fluorescence microscope (TCS-4D, Leica Corp., Heidelberg, Germany).
Statistical analysis
Data are the mean Ϯ sem. We used Student's t test to assess the significance of differences between groups. P Ͻ 0.05 was considered statistically significant.
Results
Effect of AT 1 and AT 2 receptor blockade on the expression of Ang II receptor types
Administration of an AT 1 antagonist (1.0 mg/kg⅐d) for 14 d significantly decreased AT 1 receptor binding in the adrenal medulla (about 36%) without significantly affecting the expression of AT 1 receptor protein (Fig. 1) . The treatment also significantly reduced AT 2 receptor binding (about 16%; Fig.  2 ). The reduction in AT 2 binding was associated with a 27% reduction in the expression of AT 2 receptor protein (Fig. 2) .
Administration of the AT 2 receptor antagonist PD 123319 for 14 d at the concentration of 1.0 mg/kg⅐d significantly (P Ͻ 0.05) reduced AT 2 receptor binding (about 33%) with no effect on expression of AT 2 receptor protein (Fig. 2) . Treatment with PD 123319 also failed to affect AT 1 receptor binding and expression of AT 1 receptor protein (Fig. 1) .
Effect of AT 1 and AT 2 receptor blockade on TH mRNA and adrenomedullary catecholamines
Treatment with the AT 1 receptor antagonist significantly decreased adrenal medulla TH mRNA (about 35%) and the levels of adrenal NE (about 32%; Fig. 3, A and B) . However, the AT 1 receptor blocker did not affect adrenal E content (Fig. 3A) .
Inhibition of AT 2 receptors with PD 123319 exerted effects very similar to those of AT 1 receptor blockade, namely a significant decrease in adrenal medulla TH mRNA (about 20%) and in the adrenal NE content (about 23%) without affecting the adrenal E level (Fig. 3, A and B) . 
Effect of AT 1 and AT 2 receptor blockade on expression of transcription factors
AT 1 receptor antagonism significantly decreased the levels of Fra-2 protein (about 26%) in adrenal medulla and pCREB (about 35%) and ERK2 (p-ERK2; phospho-p42 MAPK; about 17.5%) with no effect on the phosphorylated form of ERK1 (p-ERK1; phospho-p44 MAPK; Fig. 4) .
Blockade of AT 2 receptors with PD 123319 significantly decreased adrenal medulla Fra-2 protein (about 38%; Fig. 5 ). Conversely, PD 123319 treatment did not change the phosphorylation of CREB or ERK1/2 protein (Fig 5) .
Immunohistochemical localization of Ang II and AT 1 and AT 2 receptors in the adrenal medulla
We report the localization of Ang II, AT 1 , and AT 2 receptors, as determined by immunocytochemistry, in ganglion cells and chromaffin cells of the adrenal medulla. Adrenomedullary ganglion cells are very low in numbers, localized in clusters and more abundant toward the periphery of the adrenal medulla. The number of chromaffin cell is much larger than that of ganglion cells, and they are present throughout the adrenal medulla. The distribution of AT 1 , AT 2 and Ang II immunocytochemistry was not homogenous, with AT 1 and Ang II predominant in ganglion cells and AT 2 predominant in chromaffin cells. We did not attempt to precisely quantify the number of positive cells.
Both Ang II and AT 1 receptors were colocalized, with high intensity of immunofluorescence signals, in many, but not all ganglion cells (Fig. 6) . Immunofluorescence for AT 2 receptors was also high but was localized to fewer ganglion cells (Fig.  6) . In ganglion cells, whereas both Ang II and AT 1 receptors were expressed at the surface and within the cytoplasm (Fig.  6 ), we could localize AT 2 receptors only at the cellular surface (Fig. 6) . We did not find any ganglion cell containing Ang II without the concomitant expression of AT 1 receptors. AT 2 receptors were colocalized with AT 1 receptors in about half of the ganglion cells expressing AT 1 receptors (Fig. 6) .
Immunocytochemical data differed in chromaffin cells. Few chromaffin cells were positive for Ang II or AT 1 receptors, and the immunocytochemical images detected were of low intensity (Fig. 6) . Conversely, many, but not all, chromaffin cells were intensely positive for AT 2 receptors (Fig. 6 ). There were many chromaffin cells expressing AT 2 receptors but not AT 1 receptors (Fig. 6) , and there were no clearly identifiable chromaffin cells where colocalization of Ang II and AT 1 receptors, Ang II and AT 2 receptors, or AT 1 and AT 2 receptors could be demonstrated.
Discussion
Our in vivo studies demonstrate that both Ang II AT 1 and AT 2 receptors participate in the long-term maintenance of basal levels of TH transcription and NE synthesis in the rat adrenal medulla, and that the basal activation of Ang II receptors is physiologically important in this organ.
Our results are important for a number of reasons. First, our observations indicate that adrenomedullary AT 1 cholamine release, are important in the maintenance of catecholamine production, because their long-term selective inhibition is sufficient to significantly reduce TH mRNA and NE content in this organ. These findings are remarkable because in the adrenal medulla, one of the tissues expressing highest numbers of Ang II receptors in the adult rat (32), AT 1 receptors represent not more than 10% of the total Ang II receptors (14, 33) .
Second, our results are consistent with the hypothesis of a role of AT 2 receptors in the synthesis and release of adrenal catecholamines. Previous contradictory results were probably dependent on assay conditions and the species studied, with reports of the AT 2 receptor agonist CGP 42112 enhancing basal catecholamine release (34) or decreasing Ang-II induced catecholamine release without affecting their basal output (31) . We have found evidence that long-term selective, although partial, AT 2 blockade is sufficient to significantly impair the basal expression of TH mRNA and to decrease the adrenal NE content. No inhibition of AT 1 receptors occurred after administration of PD 123319, confirming the selectivity of this compound, both in vitro (25) and in vivo (24) .
It is clear that a cross-talk between AT 1 and AT 2 receptors occurs in the adrenal medulla. In this tissue, AT 1 and AT 2 receptors may act in a synergistic manner and may not be mutually opposing as originally postulated (6, 35) . Additional support for our hypothesis is based on the recent observations of increased adrenomedullary AT 1 and AT 2 receptors and catecholamine synthesis during isolation stress, and by the finding that AT 1 receptor antagonism abolished not only the stress-induced increase in catecholamine synthesis but also that of AT 2 receptor expression (16) . The increased AT 1 receptor expression in the adrenal gland of AT 2 receptor gene-deficient mice (36) could then be explained as an attempt to maintain an adequate basal catecholamine metabolism.
Our data contradict previous studies in cultured chromaffin cells that suggested counter-regulatory roles for AT 1 and AT 2 receptors in the catecholamine synthesis (37, 38) . Such a contradiction could be due to the failure of cultured chromaffin cell systems to replicate the complex cellular interaction and the differential cellular localization of the Ang II receptor types that occurs in vivo.
AT 1 and AT 2 receptor interactions are complex and may not always be synergistic. Absence of AT 2 receptor expression results in increased AT 1 receptors in the paraventricular nucleus, a change associated with increased vulnerability to stress (39) . AT 1 receptor expression is also increased in the kidney of AT 2 receptor gene deficient mice (40) . However, in this organ, whereas AT 1 receptor stimulation increases growth and vasoconstriction, increased AT 2 receptor activation has been linked to inhibition of growth and vasodilation (41) .
The third finding of interest is that AT 1 receptors are not only predominantly present in adrenomedullary ganglion neurons (42), but they are colocalized in these cells with their natural agonist, indicating a possible role as presynaptic regulators of Ang II actions and release. These catecholamine and peptide-containing cells represent an intraadrenal system of ganglion neurons (42) , part of the intrinsic innervation of the adrenal gland (43) . Our observations highlight the importance of adrenomedullary ganglion neurons in the regulation of catecholamine synthesis by adrenal chromaffin cells (44) and suggest that ganglion neurons could be one of the sites of activity of local adrenomedullary renin angiotensin system (45) .
The question remains as to how low numbers of AT 1 receptors, mainly present in the low abundance adrenomedullary ganglion neurons, have such a major impact on basal catecholamine production. It appears that at least part of the effect of AT 1 receptors on catecholamine synthesis may be lary AT 2 receptors are expressed in chromaffin cells, it is likely that the decreased AT 2 receptor expression after AT 1 receptor blockade may occur not only in the ganglion neurons, but also and predominantly in the chromaffin cells. We did not attempt to perform a quantitative immunocytochemical study in individual cells because of poor reliability of the methods for such purpose.
We have found immunocytochemical signals for AT 1 receptors close to the surface of a few chromaffin cells, which are located either on the chromaffin cell membranes or in terminals of ganglion neurons. Thus, regulation of AT 2 receptor expression by AT 1 receptors could occur by receptor cross-talk within chromaffin cells or by regulation of AT 2 receptors in chromaffin cells by changes in AT 1 -mediated ganglion neuron activity. In the adrenal medulla, the synergistic interaction between the Ang II receptor types is probably not only the result of intracellular mechanisms in cells coexpressing both receptor types but also occurs through intercellular interactions between cells expressing only AT 1 or AT 2 receptors. In addition, AT 1 receptor blockade very significant increases in Ang II synthesis (4), and increased Ang II could affect the expression of AT 2 receptors.
Although local mechanisms in the adrenal medulla appear to be most important, it is also possible that brain mechanisms could contribute to the effects of AT 1 blockade in adrenal catecholamine synthesis because the AT 1 receptor antagonist used here blocks not only peripheral but also central AT 1 receptors (23) .
The present results appear to indicate that AT 1 and AT 2 regulation of basal catecholamine synthesis is restricted to that of NE, with no influence on basal E formation, suggesting that under basal conditions E containing chromaffin cells may be less sensitive to the effects of Ang II. This finding is at odds with the clear control of both NE and E formation and release by AT 1 receptors during stress (16) and with the dual inhibition by AT 1 and AT 2 receptors of insulin-induced E release (46) . However, our findings are not surprising. Although TH is the rate-limiting enzyme for all catecholamines, different sets of chromaffin cells form NE only or NE and E, where NE may only act as E metabolic precursor, and NE and E formation and release can be regulated by selective and different mechanisms (46) . On the other hand, adrenomedullary E stores are larger than those of NE, and regulation of E formation by Ang II receptors under basal conditions could occur even in the absence of significant alterations in its tissue content.
Fourth, our findings shed some light on the mechanisms of transcriptional regulation of adrenomedullary TH by AT 1 and AT 2 receptors. It is known that a CRE-like site is involved in the Ang II stimulation of TH (20) . CREB may interact with the CRE or CRE-like elements in the TH promoter region (21) or may promote de novo synthesis of other CRE-regulated genes (c-fos and fos-family members) that could interact with the AP-1 binding sites in the TH promoter region. Different members of the AP-1 family may be involved in a stimuli and region-specific manner. Fra-2 is a mediator of stress response in the adrenal medulla after repeated immobilization stress (22) . We found that the decrease of adrenal NE and TH mRNA after long-term AT 1 receptor blockade was accompanied by significant decreases in Fra-2 and pCREB protein levels. In vitro, Ang II produced an AT 1 receptor dependent phosphorylation of CREB at serine 133 (47) and stimulation of Ang II receptors was associated with increased levels of cAMP (48) . The parallel decrease in pCREB immunoreactivity and TH mRNA in adrenal medulla after pretreatment with the AT 1 receptor blocker suggests a role for cAMP and CREB acting via cAMP response element in the TH promoter. Alternatively, pCREB may serve as a signal to mediate the transcription of fra-2 (49), which may further regulate the TH expression by binding to the AP-1 region in the TH promoter. In addition, Fra-2 expression may be also autoregulated in response to the phosphorylated status of its gene product (49) . ERK2 phosphorylates several serine and threonine residues located in the COOH-terminal region of Fra-2. Phosphorylation of Fra-2 by ERK2 converts it from an inefficient transcriptional activator to an active one. The heterodimer formed between phosphorylated Fra-2 and c-jun has very high transcriptional activity, which would induce expression of a wide range of genes through AP-1 binding site, including the one present in the fra-2 promoter (50). Indeed, after AT 1 blockade, we found a significant decrease in phosphorylated ERK2 (pERK2) that parallels the decrease in Fra-2 immunoreactive protein in adrenal medulla, indicating that this pathway may be involved in the regulation of Fra-2 protein expression and hence transcription of TH gene by Ang II.
Decreased TH transcription after AT 2 blockade is associated with substantial decreases in the expression of the Fra-2 protein in a manner similar to that which occurs after AT 1 receptor blockade. However, AT 2 blockade does not affect pCREB or pERK1/2, indicating a pathway that appears to be different to that involved in the effect of the AT 1 blockers.
In conclusion, we have demonstrated a synergistic effect of AT 1 and AT 2 receptors, through mechanisms not entirely similar, in the transcriptional regulation of NE synthesis and a clear colocalization of both receptor types in adrenomedullary ganglion neurons. A schematic representation of some of the possible sites and mechanisms presented here is outline in Fig. 7 . Our results indicate complex mechanisms for the adrenomedullary control of catecholamine synthesis and release by Ang II.
